Vericel Corp. Aktie
?
Deine Einschätzung
Vericel Corp. Aktie
Was spricht für und gegen Vericel Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von Vericel Corp. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Vericel Corp. | 0,00 % | -2,40 % | 17,34 % | 34,44 % | 28,48 % | 17,34 % | -6,45 % |
| Pacira Pharmaceuticals | -2,70 % | 0,00 % | 15,63 % | 20,65 % | 2,78 % | -31,06 % | -53,36 % |
| Supernus Pharmaceuticals | 0,00 % | 0,48 % | 8,29 % | 50,36 % | -2,79 % | 57,14 % | 81,74 % |
| Collegium Pharmaceutical Inc | -0,65 % | 2,63 % | 7,59 % | 17,29 % | -24,64 % | 63,35 % | 51,46 % |
Kommentare
News
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Michael Halpin, Chief Operating Officer of Vericel Corporation (NASDAQ:VCEL), reported the sale of 10,000 shares of Common Stock for a transaction value of approximately $402,000 on June 18, 2026
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Soleus Capital Management disclosed a significant buy of Vericel (NASDAQ:VCEL), adding 1,785,079 shares in the first quarter—an estimated $63.40 million trade based on quarterly average
Vericel Q1 Earnings Call Highlights
Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage






